Josep Vidal, MD, PhD

Josep Vidal, MD, PhD

Obesity Unit, Endocrinology and Diabetes Unit
University Hospital Clinic
Barcelona, Spain

Related Videos

What are the practical, translational implications of LEADER and how might we explain, mechanistically or physiologically, the reduction in MACE events observed in the liraglutide group? Video

What are the practical, translational implications of LEADER and how might we explain, mechanistically or physiologically, the reduction in MACE events observed in the liraglutide group?

What are the practical, translational implications of LEADER and how might we explain, mechanistically or physiologically, the reduction in MACE events observed in the liraglutide group?

What were the results of the LEADER trial? How were critical CV risk parameters such as BP, weight and HA1c levels affected? What was the take-away implication of this CV outcomes trial? Video

What were the results of the LEADER trial? How were critical CV risk parameters such as BP, weight and HA1c levels affected? What was the take-away implication of this CV outcomes trial?

What were the results of the LEADER trial? How were critical CV risk parameters such as BP, weight and HA1c levels affected? What was the take-away implication of this CV outcomes trial?

How was liraglutide titrated and what dose end point were you trying to achieve? What was the adherence rate to the study medication in the liraglutide arm? Video

How was liraglutide titrated and what dose end point were you trying to achieve? What was the adherence rate to the study medication in the liraglutide arm?

How was liraglutide titrated and what dose end point were you trying to achieve? What was the adherence rate to the study medication in the liraglutide arm?

Can you detail the characteristics of the cohorts studied in the LEADER Trial? What percentage of patients was evaluated for primary prevention vs. secondary prevention of CV events? Video

Can you detail the characteristics of the cohorts studied in the LEADER Trial? What percentage of patients was evaluated for primary prevention vs. secondary prevention of CV events?

Can you detail the background characteristics of the patient cohorts studied in the LEADER Trial? What percentage of patients was evaluated for primary prevention vs. secondary prevention of cardiovascular events?

What was the rationale and design framework for LEADER? What were the inclusionary and exclusionary criteria and what was the objective as it relates to the GLP-1 RA liraglutide? Video

What was the rationale and design framework for LEADER? What were the inclusionary and exclusionary criteria and what was the objective as it relates to the GLP-1 RA liraglutide?

What was the rationale and clinical design framework for the LEADER trial? What were the inclusionary and exclusionary criteria and what was the objective of the trial as it relates to the GLP-1 RA liraglutide?